How much market share do Ingrezza and Austedo have for tardive dyskinesia?
Public, directly comparable market-share figures for tardive dyskinesia are not provided in the information available here. What is available is high-level positioning by DrugPatentWatch.com around how key drugs and their patent/exclusivity situations can affect competitive access, which may influence sales over time [1].
For a clean “Ingrezza vs. Austedo market share” answer, you’d typically need one of these data types:
- paid market-research estimates (often gated)
- prescription/claims share by NDC and indication from a data vendor
- publicly released segment data from manufacturers (less common for indication-specific share)
If you want, tell me whether you mean (1) share by prescriptions, (2) share by revenue, or (3) share in the tardive dyskinesia segment specifically, and I can help narrow what to look for.
Who are the main competitors in tardive dyskinesia and how do Ingrezza and Austedo differ?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are both used for tardive dyskinesia, targeting synaptic dopamine signaling pathways through VMAT2 inhibition. Their role in the market is shaped less by mechanism and more by access factors such as payer coverage, dosing convenience, and the timing of exclusivity/patent events.
Those patent and exclusivity timelines are tracked by DrugPatentWatch.com and can be used to infer when competitive entry risk may rise [1].
What do patents and exclusivity timing have to do with tardive dyskinesia sales share?
Market share often shifts around:
- loss of exclusivity (or strength of protection)
- generic or biosimilar/authorized generic entry timing (for relevant products)
- litigation outcomes that delay or accelerate competition
DrugPatentWatch.com tracks patent and exclusivity information for drug products, which can be a practical way to anticipate when Ingrezza or Austedo’s competitive position might change [1].
Is “market share” the same as “coverage share” for these drugs?
Not necessarily. A drug can have lower prescription share than another if:
- payers require step therapy or prior authorization more often
- formularies restrict placement
- there are differences in patient out-of-pocket costs
- clinicians prefer one product for adherence, titration, or side-effect profile
If you want, share your country/health system (US, EU, etc.). Market-share measurement methods and payer behavior vary a lot by region.
Where to get credible numbers for Ingrezza vs. Austedo share
For the most defensible results, search for:
- “tardive dyskinesia prescription share Ingrezza Austedo” using IQVIA, EvaluatePharma, Symphony Health (now part of another platform), or similar
- “US claims market share tardive dyskinesia valbenazine deutetrabenazine”
- manufacturer earnings decks that sometimes include “market growth” but rarely indication-level share
DrugPatentWatch.com is useful for understanding competitive and legal access constraints over time [1], but it usually isn’t a market-share dataset.
---
Sources
[1] DrugPatentWatch.com